Bile acid-induced Mallory body formation in drug-primed mouse liver.
Chronic cholestasis is associated with retention of bile acids and profound cytoskeletal alterations in hepatocytes including Mallory body (MB) formation. The mechanisms responsible for MB formation in cholestatic liver diseases are unclear. The aim of our study was to determine the relevance of cholestasis and bile acids for MB formation. For this purpose mice received a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diet for 2.5 months to induce MB formation. After recovery from DDC intoxication for 4 weeks followed by disappearance of MBs, these drug-primed mice were subjected to DDC refeeding, common bile duct ligation (CBDL), and feeding of a cholic acid (CA)-supplemented diet for 7 days, respectively. Cytokeratin (CK) 8 and CK 18 expression was studied by competitive reverse transcriptase-polymerase chain reaction and Western blot analysis. Cytoskeletal alterations of hepatocytes and MB formation were monitored by immunofluorescence microscopy and immunohistochemistry using CK-, ubiquitin-, and MB-specific antibodies. Like DDC refeeding, both CBDL and CA feeding of drug-primed mice significantly increased CK 8 and CK 18 mRNA and protein levels (with excess of CK 8) and resulted in ubiquitination and abnormal phosphorylation of CKs. Furthermore, CBDL and CA feeding resulted in rapid neoformation of MBs in drug-primed mice. It is concluded that MB formation in cholestatic liver diseases may be triggered by the action of potentially toxic bile acids.
Fickert
Peter
P
Department of Medicine, Karl-Franzens University, Auenbruggerplatz 25, A-8036 Graz, Austria.
Trauner
Michael
M
Fuchsbichler
Andrea
A
Stumptner
Conny
C
Zatloukal
Kurt
K
Denk
Helmut
H
D000818:Animals; D001647:Bile Acids and Salts / Q000378:metabolism*; D001652:Bile Ducts / Q000601:surgery; D002779:Cholestasis / Q000378:metabolism / Q000473:pathology; D019826:Cholic Acid / Q000008:administration & dosage / Q000378:metabolism; D003997:Dicarbethoxydihydrocollidine / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004032:Diet; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure*; D006801:Humans; D002479:Inclusion Bodies / Q000378:metabolism / Q000648:ultrastructure*; D007633:Keratins / Q000235:genetics / Q000378:metabolism; D008026:Ligation; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure*; D008297:Male; D051379:Mice; D010766:Phosphorylation; D025801:Ubiquitin / Q000378:metabolism
D001647:Bile Acids and Salts; D025801:Ubiquitin; D003997:Dicarbethoxydihydrocollidine; D007633:Keratins; D019826:Cholic Acid